136 related articles for article (PubMed ID: 20210346)
1. New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration.
Ché C; Yang G; Thiot C; Lacoste MC; Currie JC; Demeule M; Régina A; Béliveau R; Castaigne JP
J Med Chem; 2010 Apr; 53(7):2814-24. PubMed ID: 20210346
[TBL] [Abstract][Full Text] [Related]
2. Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma.
Xin H; Jiang X; Gu J; Sha X; Chen L; Law K; Chen Y; Wang X; Jiang Y; Fang X
Biomaterials; 2011 Jun; 32(18):4293-305. PubMed ID: 21427009
[TBL] [Abstract][Full Text] [Related]
3. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain.
Shao K; Huang R; Li J; Han L; Ye L; Lou J; Jiang C
J Control Release; 2010 Oct; 147(1):118-26. PubMed ID: 20609375
[TBL] [Abstract][Full Text] [Related]
4. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles.
Xin H; Sha X; Jiang X; Zhang W; Chen L; Fang X
Biomaterials; 2012 Nov; 33(32):8167-76. PubMed ID: 22889488
[TBL] [Abstract][Full Text] [Related]
5. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer.
Ke W; Shao K; Huang R; Han L; Liu Y; Li J; Kuang Y; Ye L; Lou J; Jiang C
Biomaterials; 2009 Dec; 30(36):6976-85. PubMed ID: 19765819
[TBL] [Abstract][Full Text] [Related]
6. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
[TBL] [Abstract][Full Text] [Related]
7. Enhanced blood-brain-barrier penetrability and tumor-targeting efficiency by peptide-functionalized poly(amidoamine) dendrimer for the therapy of gliomas.
Liu C; Zhao Z; Gao H; Rostami I; You Q; Jia X; Wang C; Zhu L; Yang Y
Nanotheranostics; 2019; 3(4):311-330. PubMed ID: 31687320
[TBL] [Abstract][Full Text] [Related]
8. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity.
Rousselle C; Smirnova M; Clair P; Lefauconnier JM; Chavanieu A; Calas B; Scherrmann JM; Temsamani J
J Pharmacol Exp Ther; 2001 Jan; 296(1):124-31. PubMed ID: 11123372
[TBL] [Abstract][Full Text] [Related]
9. Integrated platform for brain imaging and drug delivery across the blood-brain barrier.
Iqbal U; Abulrob A; Stanimirovic DB
Methods Mol Biol; 2011; 686():465-81. PubMed ID: 21082388
[TBL] [Abstract][Full Text] [Related]
10. Fullerenol-cytotoxic conjugates for cancer chemotherapy.
Chaudhuri P; Paraskar A; Soni S; Mashelkar RA; Sengupta S
ACS Nano; 2009 Sep; 3(9):2505-14. PubMed ID: 19681636
[TBL] [Abstract][Full Text] [Related]
11. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines.
Johnstone SA; Gelmon K; Mayer LD; Hancock RE; Bally MB
Anticancer Drug Des; 2000 Apr; 15(2):151-60. PubMed ID: 10901303
[TBL] [Abstract][Full Text] [Related]
12. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell).
Meyer-Losic F; Quinonero J; Dubois V; Alluis B; Dechambre M; Michel M; Cailler F; Fernandez AM; Trouet A; Kearsey J
J Med Chem; 2006 Nov; 49(23):6908-16. PubMed ID: 17154520
[TBL] [Abstract][Full Text] [Related]
13. Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells.
Noguchi M; Kabayama K; Uemura S; Kang BW; Saito M; Igarashi Y; Inokuchi J
Glycobiology; 2006 Jul; 16(7):641-50. PubMed ID: 16571667
[TBL] [Abstract][Full Text] [Related]
14. Retro-inverso isomer of Angiopep-2: a stable d-peptide ligand inspires brain-targeted drug delivery.
Wei X; Zhan C; Chen X; Hou J; Xie C; Lu W
Mol Pharm; 2014 Oct; 11(10):3261-8. PubMed ID: 24673510
[TBL] [Abstract][Full Text] [Related]
15. Effects of gamma- and hydroxypropyl-gamma-cyclodextrins on the transport of doxorubicin across an in vitro model of blood-brain barrier.
Monnaert V; Betbeder D; Fenart L; Bricout H; Lenfant AM; Landry C; Cecchelli R; Monflier E; Tilloy S
J Pharmacol Exp Ther; 2004 Dec; 311(3):1115-20. PubMed ID: 15280439
[TBL] [Abstract][Full Text] [Related]
16. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
Holm B; Sehested M; Jensen PB
Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
[TBL] [Abstract][Full Text] [Related]
17. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
18. Identification and design of peptides as a new drug delivery system for the brain.
Demeule M; Régina A; Ché C; Poirier J; Nguyen T; Gabathuler R; Castaigne JP; Béliveau R
J Pharmacol Exp Ther; 2008 Mar; 324(3):1064-72. PubMed ID: 18156463
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity.
Liang JF; Yang VC
Bioorg Med Chem Lett; 2005 Nov; 15(22):5071-5. PubMed ID: 16168650
[TBL] [Abstract][Full Text] [Related]
20. Antitumor agents. Part 235: Novel 4'-ester etoposide analogues as potent DNA topoisomerase II inhibitors with improved therapeutic potential.
Xiao Z; Vance JR; Bastow KF; Brossi A; Wang HK; Lee KH
Bioorg Med Chem; 2004 Jun; 12(12):3363-9. PubMed ID: 15158805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
